Home >> Tag Archives: Binding Site

Tag Archives: Binding Site

Binding Site expands coagulation testing line

November 2019—Binding Site’s Immunologicals Group has expanded its line of antibodies and antigens for human coagulation testing applications. Prothrombin and glycerol-free prothrombin proteins are available as antigens, and antibody products include anti-human factor H, factor I, fibrinogen, fibronectin, plasminogen, prothrombin, thrombin, and von Willebrand factor.

Read More »

Binding Site TBE antigens, purified human CRP

August 2019—Binding Site’s Immunologicals Group added two native tick-borne encephalitis viral antigens to its line of products for in vitro diagnostic manufacturing and research applications. The standard version of the antigen as well as the premium version are for use as components in enzyme immunoassay testing procedures.

Read More »

Recombinant antigens, monoclonal antibodies

March 2019—Binding Site’s Immunologicals Group has added five recombinant Epstein-Barr virus antigens to its line of products for in vitro diagnostic manufacturing and research applications. The EBV capsid antigen P18; EBV capsid antigen P23; EBV early antigen P138; EBV early antigen P54; and EBV nuclear antigen EBNA1, P72 have been designed for use as components within solid phase enzyme immunoassay test procedures, especially ELISA. The antigens are E. coli source-derived recombinant proteins.  

Read More »

Binding Site antigens, antibodies

November 2018—Binding Site’s Immunologicals Group has introduced highly purified Borrelia and chikungunya glycoprotein antigens for use in IVD manufacturing and research applica-tions and as a component within solid phase ELISA-based immunoassay test procedures.

Read More »

Disease state sera, plasma products

August 2018—Binding Site’s Immunologicals Group has added infectious and contagious disease state sera and plasma products to its line of products. The human-based serum/plasma biological materials cover a variety of infectious and contagious disease state conditions, including Epstein-Barr virus, influenza, measles, mumps, TORCH, and West Nile. Evaluation samples are available and all materials come in bulk formats for use in the manufacturing of calibration and quality control materials. The company offers comprehensive data on analyte positives and negatives along with a certificate of analysis. In a separate release, the Immunologicals Group announced it has expanded its antibody and antigen product offerings for human coagulation and complement applications.

Read More »

Parainfluenza virus antigens

July 2018—Binding Site’s Immunologicals Group has added three parainfluenza virus antigens for in vitro diagnostic manufacturing and research applications. The Parainfluenza Virus Type 1, Type 2, and Type 3 antigens have been designed for use in solid phase enzyme immunoassay test procedures, especially ELISAs.

Read More »

IgG subclass antibodies

June 2018—Binding Site’s Immunologicals Group announced the availability of affinity-purified, unconjugated, anti-human antibodies to the IgG subclasses, including IgG1, IgG2, IgG3, and IgG4, for IVD research use in solid phase enzyme immunoassay based test methods, especially ELISAs, and other potential testing applications.

Read More »

Polyclonal antibodies, 5/18

May 2018—Binding Site’s Immunologicals Group announced the addition of sheep anti-human, monkey adsorbed, IgG polyclonal antibodies designed for use with a variety of testing procedures, especially enzyme immunoassays, for research applications.

Read More »

Recombinant antigens, monoclonal antibodies, 4/18

April 2018—Binding Site’s Immunologicals Group has added three recombinant Treponema pallidum antigens to its in vitro diagnostic product line: T. pallidum TpN-15, TpN-17, and TpN-47. The antigens are derived and sourced from E. coli via culture and then purified to a level of >95 percent and confirmed via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

Read More »

Bordetella pertussis antigens for IVD use

March 2018—Binding Site’s Immunologicals Group has added three Bordetella pertussis (VZV) antigens to its offering of products for in vitro diagnostic manufacturing and research applications. The Bordetella pertussis FHA, Bordetella pertussis Toxin PT, and Bordetella pertussis Whole-Cell Antigens have been designed for use as integral components within solid phase enzyme immunoassay test procedures.

Read More »

Recombinant parvovirus antigens, 12/17

December 2017—Binding Site’s Immunologicals Group has added eight recombinant antigens to its offering of products for in vitro diagnostic manufacturing and research applications. The recombinant Parvovirus NS1, Parvovirus VP1, Parvovirus VP2, Parvovirus VP2-VLP, Parvovirus PepA (VP1 unique), Parvovirus PepB (VP2 C-term), Parvovirus PepC (VP1 N-term), and Parvovirus PepD (VP1 C-term) have been designed for use as an integral component within solid phase enzyme immunoassay test procedures, including ELISA.

Read More »

Disease state sera, 12/17

December 2017—Binding Site’s Immunologicals Group offers a comprehensive line of disease state sera in its portfolio of products available to in vitro diagnostic manufacturers and clinical research facilities. The line of products follows all current regulatory and quality standards guidelines and provides materials from a variety of disease state conditions, including ANAs, ANCAs, aPLs, ENAs, infectious and contagious diseases, inflammation markers, and autoantibodies focused on a variety of human organs and tissues.

Read More »

Varicella zoster virus antigens, 11/17

November 2017—Binding Site’s Immunologicals Group has added two varicella zoster virus antigens to its line of products for in vitro diagnostic manufacturing and research applications. Both the standard VZV antigen and the VZV glycoprotein antigen have been designed for use as integral components within solid phase enzyme immunoassay test procedures.

Read More »

HIV P24 monoclonal antibodies, 8/17

August 2017—Binding Site’s Immunologicals Group has added a number of monoclonal antibodies used for the clinical testing of human immunodeficiency virus to its line of in vitro diagnostic manufacturing and clinical research applications. The HIV P24 275, HIV P24 114, and HIV P24 9.23.11.8.9.4 anti-human monoclonal antibodies have been designed for use as an integral component within a number of enzyme immunoassay testing procedures.

Read More »

Infectious diseases monoclonal antibodies, 7/17

July 2017—The Binding Site’s Immunologicals Group has completed a major expansion to its monoclonal antibody product offerings. In addition to the company’s conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, a number of monoclonal antibodies focused on infectious diseases, including CMV, hepatitis (A, B, C, and D), herpes, HIV, rubella, and toxoplasma have been introduced.

Read More »

Antigens, special protein reagents, 10/16

October 2016—Binding Site’s Immunological Group announced the addition of two rubella antigens and a cytomegalovirus antigen along with the availability of special protein reagents to in vitro diagnostic manufacturers. The rubella antigens are derived and sourced from infected cells, via culture, which are then treated by UV irradiation to inactivate the pathogenic components. The ultra-purified and ultra-sensitive variant is ideal for the detection of IgM antibodies. The antigens are designed to benefit the needs of biopharmaceutical, clinical, and life science researchers, as well as manufacturers of IVD test kits, and exhibit exceptional purity levels as a result of cross-flow, ultra-filtration and centrifugation techniques.

Read More »

Binding Site, Rockland enter distribution agreement, 6/16

June 2016—The Binding Site Group has entered into an exclusive, definitive agreement with Rockland Immunochemicals to grant Rockland global distribution rights for Binding Site’s line of animal-focused radial immunodiffusion test kits. The RID immunoassay kits incorporate monospecific antibodies in an agarose gel to provide accurate quantitation.

Read More »

Resources for in vitro diagnostics, 9/15

The Binding Site announced the formation of its new Immunologicals Group. Formerly known as OEM, this new team will have a broad remit to encompass the sales, marketing, and support of specialist antibodies, antigens, disease state sera, and services to IVD manufacturers, research scientists, and academic facilities.

Read More »

Ro (SSA) antigen, 4/15

April 2015—The Binding Site, through its arrangement with Arotec Diagnostics, offers an Ro (SSA) antigen designed for use as a component in solid phase ELISA-based immunoassay test procedures for the detection of anti-Ro (SSA) antibodies for use in research and in vitro diagnostic manufacturing applications.

Read More »

Reagents, antibodies, and antigens, 9/14

September 2014—The Binding Site announced an enhancement to its Rheumatoid Factor/Immunoglobulin-G Absorbent Reagent specifically designed for use in conjunction with infectious disease immunodiagnostic procedures. The RF/IgG Absorbent Reagent can now be used to equally test and analyze serum and plasma samples without compromising test results.

Read More »

Proteinase–3 (cANCA) native autoantigen, 8/14

August 2014—A Proteinase–3 (cANCA) native autoantigen for the in vitro diagnostics market is available from The Binding Site. Expressly designed for use as an integral component in solid-phase, ELISA-based immunoassay test procedures, the Proteinase–3 (cANCA) native autoantigen is for clinical and life-science researchers, medical laboratory professionals, and manufacturers of in vitro diagnostic immunoassay kits and tests for autoimmune conditions.

Read More »

ELISA procedure to quantify human IgG, 9/13

The Binding Site now offers a specifically formulated and optimized ELISA procedure for the quantitation of intact human IgG from matrices containing non-human proteins. The assay is for clinical, biopharmaceutical, and medical researchers. The ELISA uses sheep polyclonal antibody, specific to the Fc and light chain regions of human IgG for capture and detection respectively, ensuring that only intact human ...

Read More »

TMB substrate-chromogen, 9/13

The Binding Site now offers a substrate-chromogen containing 3,3’,5,5’-tetramethylbenzidine (TMB). Designed for use as an integral component in peroxidase-based, colorimetric techniques, the TMB chromagen-substrate is for use in enzyme immunoassay test procedures. The TMB substrate-chromagen demonstrates decreased sensitivity to light when compared with other peroxidase chromogens and can be developed without any special precautions. Offered in a liquid-stable, ready-to-use format, ...

Read More »

Human protein antibodies, 9/13

The Binding Site now offers a specialized line of anti-human serum protein antibodies. Through the use of a patented technique, which yields highly specific antibodies, all available products display a high degree of purity, shelf-life stability, and lot-to-lot consistency. The range of specialized antibodies includes those involved in blood coagulation, complement activation, acute-phase reactants, immunoglobulin response, and others. The antibodies ...

Read More »

Myeloperoxidase antigen, 6/13:97

Working in conjunction with Arotec Diagnostics, The Binding Site offers myeloperoxidase (pANCA) antigen. Antibodies to myeloperoxidase have been observed in systemic vasculitis, glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease. Elevated plasma levels also have been reported in acute coronary syndromes and with some malignancies.

Read More »
CAP TODAY
X